The NHS has been touting the success of Palantir’s £330 million federated data platform (FDP) as a catalyst for better patient care, yet a cache of freedom‑of‑information data reveals a stark disconnect: 29 hospital trusts listed as “realising benefits” say they are either not live on the system or are not using any of its applications at all. Senior health officials have called the discrepancy “very misleading”, while MPs and campaigners are pressing for the contract to be scrapped and replaced with a UK‑based solution. The controversy is now drawing scrutiny from regulators, Parliament and the very trusts that were supposed to be its early adopters.
The gap between NHS claims and trust reality
NHS England’s website states that 137 trusts are “live” with the FDP, and a subset of 29 are said to be “realising benefits”. However, internal documents obtained by the medical charity Medact show that these trusts do not recognise the system as operational. The contrast has prompted one senior health official to label the situation “very misleading”. The official’s concern echoes broader worries about the evidence base for the £330 million investment, especially after NHS England admitted it could not prove a causal link between the platform and the claimed rise in operations.
Trust responses reveal limited adoption
The FOI replies from individual trusts paint a picture of delayed or halted implementation:
– Epsom and St Helier said it was “not using FDP at the moment”.
– Kent and Medway explained the trust “has been focused on other priorities … the FDP is not currently live”.
– Mersey Care reported they had “not yet gone live with the FDP”.
– Nottingham University Hospitals noted “no implementation timeline has been agreed”.
– University Hospitals of North Midlands bluntly stated: “FDP is not live. We do not intend to roll it out in the future.”
Torbay and South Devon NHS Foundation Trust added a nuance: it is “not currently operationally using the FDP” but is recorded as “live” because the underlying infrastructure supports data submission rather than active patient‑care tools. These statements directly contradict the NHS’s narrative that the platform is already delivering tangible improvements.
Political and regulatory backlash intensifies
The mounting evidence has sparked a bipartisan push to reconsider the contract. Health Secretary Yvette Cooper faces calls from MPs and campaigners to invoke the 2027 break clause and launch an open competition for a UK‑owned provider. Chi Onwurah, chair of the Commons science and technology committee, warned that “if many NHS trusts don’t see the value of the FDP, serious questions need to be asked about whether the hype surrounding Palantir’s products matches reality.” She urged the government to activate the break clause and replace the system with a locally controlled alternative.
Regulatory bodies are also taking notice. The Office for Statistics Regulation (OSR) has opened a casework file after NHS England conceded it could not prove cause and effect between the platform and the reported 117 539 extra operations. The OSR’s investigation adds a layer of formal scrutiny to the claims that have been used to justify the multi‑million‑pound deal.
Palantir defends its role amid mounting scrutiny
Palantir’s UK and Europe chief executive, Louis Mosley, has dismissed criticism as “politics over patients” and coined the term “Palantir Derangement Syndrome” to describe opposition. The company points to statistics it says demonstrate real‑world impact: 117 000 additional operations, a 14.3 % reduction in discharge delays for long‑stay patients, and a 5.6 % improvement in the proportion of people learning their cancer status within 28 days. Mosley argues that ending the contract would jeopardise these gains.
Palantir has also bolstered its lobbying efforts, hiring former Labour deputy leader Tom Watson as a full‑time senior lobbyist. Watson has been posting videos on X to counter “myths” about the platform, particularly concerns about vendor lock‑in. Critics, including Green party leader Zack Polanski, have labelled the appointment “beyond ridiculous”. Meanwhile, the company’s billionaire founder Peter Thiel has long championed a vision of technology reshaping governance, a philosophy that underpins Palantir’s aggressive market entry into public services.
Medical professionals are not uniformly supportive. Marc Farr, chair of the NHS Chief Data and Analytics Officers Network, expressed concern: “I am concerned to hear that there are 29 trusts reported as receiving benefits but when asked are not actually using the tool. It is great that a number of trusts that have adopted the FDP are benefiting from this nationally funded programme, but it is crucial for public support … that benefits are reported accurately, transparently and in a way that can be properly verified.”
Why it Matters
The discrepancy between NHS England’s promotional claims and the lived experience of its constituent trusts strikes at the heart of patient safety and public confidence. When a multi‑hundred‑million‑pound AI platform is touted as a catalyst for life‑saving care, the evidence must be both robust and transparent. The current situation not only risks wasting scarce healthcare resources but also threatens to erode trust in the NHS’s ability to responsibly adopt emerging technologies. As the debate intensifies, the stakes are clear: the future of patient data management, the integrity of public procurement, and the broader question of whether foreign‑owned AI firms should play a central role in delivering core health services. The outcome will shape how the NHS balances innovation with accountability for years to come.
